APY Therapeutics
Biotechnology Research • 
North Brunswick, New Jersey, United States • 1-10 Employees
Company overview
| Headquarters | North Brunswick, New Jersey, United States |
| Website | |
| NAICS | 541714 |
| Founded | 2025 |
| Employees | 1-10 |
Key Contact at APY Therapeutics
Richard H. Ebright
Founder and CEO
About APY Therapeutics
APY Therapeutics is developing arylmyxopyronins–APYs–as novel first-in-class oral treatments for lower-respiratory-tract infections and skin-and-soft-tissue bacterial infections. APY Therapeutics is a member of INCATE (INCubator for Antibacterial Therapies in Europe).
$
APY Therapeutics revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
C-Suite
Employees by Department
APY Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
APY Therapeutics has never raised funding before.
Israel
Canada
Australia
Saudi Arabia
New ZealandFrequently asked questions
APY Therapeutics is located in North Brunswick, New Jersey, US.
APY Therapeutics was founded in 2025, making it 1 years old. The company has established itself as a significant player in its industry over this time.
APY Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
